Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Stable Coronary Artery Disease CAD Clear all
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Performance of the Acoustic Based CADScor System in Coronary Artery Disease

NCT06655779
View directory record Official record
Conditions
Coronary Artery Disease, Angina (stable)
Interventions
Acoustic Detection of Blood Flow
Diagnostic Test
Lead sponsor
INTEGRIS Baptist Medical Center
Other
Eligibility
30 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease

NCT02601560
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
MEDI6012, Placebo SC, Placebo IV
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
40 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
Anniston, Alabama • Jacksonville, Florida • Port Orange, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2018 · Synced Jul 23, 2026, 10:04 AM EDT
Terminated Phase 4 Interventional

Rosiglitazone and Metformin: Outcomes Trial in Nondiabetic Patients With Stable Coronary Syndromes (Romance) Pilot Study

NCT00343395
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
AVANDAMET
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Mar 16, 2011 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 4 Interventional Results available

Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study

NCT03489863
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Ticagrelor
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of CMX-2043 in Subjects Undergoing Coronary Reperfusion Therapy

NCT00984802
View directory record Official record
Conditions
Stable Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
CMX-2043, Placebo control
Drug
Lead sponsor
Ischemix, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Worcester, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 19, 2011 · Synced Jul 23, 2026, 10:04 AM EDT
Recruiting Not applicable Interventional

The Effect of Mindfulness on Vascular Inflammation in Stable Coronary Disease

NCT04505865
View directory record Official record
Conditions
Atherosclerosis, Stress, Inflammation
Interventions
Stress Reduction
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jul 23, 2026, 10:04 AM EDT
Recruiting Phase 4 Interventional

Etomidate Versus Propofol in CABG Surgery

NCT06068764
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Etomidate, Propofol
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)

NCT00543400
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
M118, Unfractionated Heparin
Drug
Lead sponsor
Momenta Pharmaceuticals, Inc.
Industry
Eligibility
19 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
37
States / cities
Little Rock, Arkansas • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders

NCT00642811
View directory record Official record
Conditions
Stable Coronary Artery Disease
Interventions
Ticagrelor, Clopidogrel, Aspirin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Jonesboro, Arkansas • Ormond Beach, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2011 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin

NCT00528411
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor Tablets, Clopidogrel (over encapsulated) capsule, Aspirin Tablets
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Baton Rouge, Louisiana • Baltimore, Maryland • Towson, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2012 · Synced Jul 23, 2026, 10:04 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Studying the Efficacy of Aspirin & Clopidogrel in Healthy Subjects With Stable Coronary Artery Disease.

NCT01011257
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Asprin, Clopidogrel
Drug
Lead sponsor
Neil Kleiman, MD
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 4 Interventional Results available

A Pharmacodynamic Study With Ticagrelor in African American Patients

NCT01523392
View directory record Official record
Conditions
Stable Coronary Artery Disease
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
8
States / cities
Newark, Delaware • Wilmington, Delaware • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Adults With Stable Coronary Heart Disease

NCT03351738
View directory record Official record
Conditions
Stable Coronary Heart Disease
Interventions
MEDI5884, Placebo
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
45 Years to 80 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
23
States / cities
Anniston, Alabama • Huntsville, Alabama • El Cajon, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2020 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 2 Interventional

Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease

NCT01058018
View directory record Official record
Conditions
Atherosclerosis, Coronary Artery Disease
Interventions
RVX000222, Placebo
Drug
Lead sponsor
Resverlogix Corp
Industry
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2023 · Synced Jul 23, 2026, 10:04 AM EDT
Terminated No phase listed Observational

Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable CAD in Post MI Patients

NCT01866904
View directory record Official record
Conditions
Stable Coronary Artery Disease (CAD), Myocardial Infarction
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years and older
Enrollment
9,284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
34
States / cities
Huntsville, Alabama • Los Angeles, California • Santa Ana, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2018 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 4 Interventional Results available

Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina

NCT01425359
View directory record Official record
Conditions
Angina Pectoris, Coronary Artery Disease, Type 2 Diabetes Mellitus
Interventions
Ranolazine, Ranolazine placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
949 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
20
States / cities
Little Rock, Arkansas • Merced, California • Moreno Valley, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Jul 23, 2026, 10:04 AM EDT
Completed No phase listed Observational

Angina Prevalence and Provider Evaluation of Angina Relief

NCT01705054
View directory record Official record
Conditions
Stable Coronary Artery Disease CAD
Interventions
Not listed
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years and older
Enrollment
1,246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Jul 23, 2026, 10:04 AM EDT
Recruiting Not applicable Interventional

MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation

NCT05933083
View directory record Official record
Conditions
Myocardial Infarction, Heart Failure, Systolic, Heart Valve Diseases, Angina, Stable, Coronary Artery Disease, Heart Transplant
Interventions
In-person cardiac rehabilitation, Telehealth cardiac rehabilitation
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
San Francisco, California • Denver, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 4 Interventional Results available

Prasugrel/Clopidogrel Maintenance Dose Washout Study

NCT01014624
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Clopidogrel
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 74 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
La Jolla, California • Jacksonville, Florida • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2021 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 4 Interventional

Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients

NCT01706510
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
Rapid City Regional Hospital, Inc
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rapid City, South Dakota
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 3 Interventional

Trial of Lycopene/Ateronon for Secondary Prevention of Coronary Heart Disease

NCT00939237
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
Ateronon, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Jul 23, 2026, 10:04 AM EDT
Terminated Not applicable Interventional

Remote Ischemic Preconditioning to Prevent Contrast Nephropathy

NCT02674451
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Remote ischemic preconditioning
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

F-18 Rhodamine 6G PET Imaging for Myocardial Blood Flow

NCT04528758
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Rhodamine 6G
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
21 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 23, 2026, 10:04 AM EDT
Not listed Phase 2Phase 3 Interventional

Effects of Different Doses of Ticagrelor on Platelet Aggregation and Endothelial Function in Diabetic Patients With Stable Coronary Artery Disease

NCT02889549
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
ticagrelor, clopidogrel
Drug
Lead sponsor
First Affiliated Hospital of Harbin Medical University
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Jul 23, 2026, 10:04 AM EDT